How long does it usually take to see the effects of Mirdametinib after taking it?

Mirdametinib is an oral MEK1/2 inhibitor mainly used to treat neurofibromatosis type 1 (NF1)-related plexiform neurofibromas (PN) and other diseases. It inhibits the abnormal growth and expansion of tumor cells by blocking the key MEK enzyme activity in the MAPK signaling pathway. Due to its strong targeting and clear mechanism of action, midametinib is considered to be one of the important treatment options for NF1 patients. So, how long it takes to see the effects after taking the medicine is a matter of great concern to patients and their families.

Based on existing clinical trials and research data, the initial response to midametinib in the treatment of NF1-related plexiform neurofibromas usually begins to appear within 1 to 2 months after taking the drug. Some patients may experience reduced pain, relief of compression symptoms, or improved mobility in the tumor area at this stage. Especially in children and adolescent patients, pain control and tumor softening are more obvious, which provides an early basis for clinical judgment of efficacy.

From an imaging perspective, measurable reduction in tumor volume is generally more obvious after 3 to 6 months of treatment. According to the results of clinical studies (such as SPRAY, NCI trials), midametinib can achieve a tumor volume reduction of 20% or more in about 40% of patients. More importantly, this reduction is often durable and accompanied by functional improvements, such as enhanced neurological function and improved motor ability. However, due to the slow growth and complex morphology of PN, not all patients can see significant radiographic changes in the short term.
In addition, the emergence of efficacy is also affected by multiple factors, including the location and size of the tumor, the age of the patient, and whether it is combined with other diseases. Some patients may take longer (more than 6 months) to achieve stable remission. There are also a small number of patients who have a weak response to midametinib due to individual differences, and may have insignificant efficacy or even need to change the treatment plan. Therefore, MRI assessments, pain scores and quality of life surveys need to be carried out regularly during the course of treatment to dynamically track the treatment effect and guide whether to continue or adjust medication.
Reference: https://www.drugs.com/